Professor John Gribben

Professor John Gribben graduated from the University of Glasgow in 1980. He subsequently trained in Haematology at University College London and in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, where he remained on the faculty for 17 years before returning to the UK. He specialises in haematological cancers including lymphomas, leukaemias and bone marrow transplantation and immunotherapy approaches including CAR-T cells. He holds the Hamilton Fairley Chair of Medical Oncology at Barts and the London School of Medicine and Dentistry and his NHS post is as Honroary Consultant Haematologist and Medical Oncologist Barts and The London NHS Trust. He is the author of more than 500 articles and chapters in peer-reviewed publications and has a global reputation for his work in researching new drugs and forms of cancer treatment. He has grant funding from The National Cancer Institute and Cancer Research UK for pioneering studies in leukaemia and lymphoma. He takes up his role as President of the European Hematology Association (EHA) for 2 years from June 2019 is serves on the EHA Executive Board. He is Chair of the international workshop for non-Hodgkin’s lymphoma (iwNHL) and co-chair of the international workshop for CAR T cells (iwCART). He was an Editor of Blood from 2007-2014. He is a Trustee of the London Clinic.

He specialises in haematological cancers including lymphomas, leukaemia's and bone marrow transplantation